Pancreatic Adenocarcinoma Treatment Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Pancreatic Adenocarcinoma Treatment Market in 2025 is estimated at USD 2.92 billion. The global market size was more than USD 2.62 billion in 2024 and is anticipated to grow at a CAGR of over 14.3%, reaching USD 14.89 billion revenue by 2037. North America is likely to secure USD 4.91 billion by 2037, driven by the rising incidence of pancreatic adenocarcinoma.
The market growth is driven by rising prevalence of pancreatic adenocarcinoma among people across the world. The changing lifestyle habits and adoption of alcohol are estimated to boost the market demand. Moreover, increasing prevalence of obesity will impel the market revenue. As of 2022 reports, more than 1 billion population across the globe are suffering from obesity with over 600 million adults, 40 million children, and more than 300 million adolescents.
Additionally, poor diet and unhealthy lifestyle practices are fueling the market growth. Furthermore, increasing demand for packed foods and beverages across the globe will propel the market size. The lack of therapeutic procedures and early diagnostic tests for pancreatic adenocarcinoma is also estimated to create opportunities for the market expansion.
Pancreatic Adenocarcinoma Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Pancreatic Disorders owing to Germline Mutations – In the U.S. more than 60,000 people are diagnosed with pancreatic cancer as of 2023.
- Rising Geriatric Population across the World with Reduced Immunity – As per the estimations in 2023, more than 1 in 6 people in America which is 80 million people are now the age 65 and above.
- Increasing Incidence of Cancers related to the Digestive System and Stomach owing to Unhealthy Foods – The number of cancer cases reported in the year 2019 across the U.S. was over 1,752,700 and 600,000 people died from cancer.
- Increasing use of Chemotherapy and Radiotherapy Treatments around the Globe – More than 50% of cancer patients are estimated to receive radiation therapy as of 2023 estimations.
- Rising Healthcare Expenditure with Improved Infrastructure Facilities – The healthcare expenditure of the U.S. was estimated to increase by more than 25% in the year 2021 with a value of over USD 4 trillion.
Challenges
- Rising Cost of Drug Development and Treatment
- Side Effects of Radiation and Chemotherapy –
The side effects of chemotherapy include pain, dizziness, fever, vomiting, and frequent bowel movement and the side effects of radiation therapy include diarrhea, shortness of breath, change in taste, and urinary and bladder problems. All these factors are estimated to be the reason for the hampering of market growth.
- Stringent Government Regulatory Guidelines
Pancreatic Adenocarcinoma Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
14.3% |
|
Base Year Market Size (2024) |
USD 2.62 billion |
|
Forecast Year Market Size (2037) |
USD 14.89 billion |
|
Regional Scope |
|
Pancreatic Adenocarcinoma Treatment Segmentation
Type (Chemotherapy, Targeted Therapy)
The chemotherapy segment is estimated to gain largest market share of about 40% by 2037. The segment growth can be attributed to increasing number of patients in the need of chemotherapy. Chemotherapy is the first line of treatment in cancer disorders along with medications. More than 26% of people across the UK are estimated to have chemotherapy as the primary treatment for pancreatic cancer as of 2020.
The increasing use of chemotherapy and targeted therapy for cancer cell isolation in tumor formation will propel the market expansion. Further, the increasing presence of competent practitioners and increasing medical facilities across the world are expected to drive segment growth. Moreover, the growing number of hospitals and clinics that provide chemotherapy with advanced equipment and decent infrastructure will fuel the segment revenue.
Affected Area (Exocrine, Endocrine)
The exocrine segment is predicted to account for around 56% share by 2037. The pancreas is mostly composed of exocrine cells compared to endocrine cells in the body. The segment growth is attributed to increasing prevalence of exocrine cancers. More than 90% of pancreatic cancers across the world are exocrine tumors as of estimations in 2022. Cancer in the ducts affects the exocrine cells of the pancreas causing exocrine cancer. High awareness and technological advancements in endocrine cancer diagnostics or tumor diagnosis among people will boost the segment growth. The increasing privatization across the world and an increasing number of hospitals with chemotherapy and radiology treatment will fuel the market revenue.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Affected Area |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPancreatic Adenocarcinoma Treatment Industry - Regional Synopsis
North American Market Forecast
The pancreatic adenocarcinoma treatment market share in North America is anticipated to exceed 33% by 2037. The market domination is driven by increasing prevalence of pancreatic adenocarcinoma disease across the region. The increasing population across the region along with the changing food habits will propel the market size. The growing cancer rate across the region with a high number of patients under treatment will fuel the market growth. Also, the increased number of key players in the region interested in investment in the healthcare sector is estimated to hike the market growth across the region.
The presence of a large population suffering from the disease and increasing acceptance of pancreatic treatment procedures in the region. As per the National Cancer Institute, in 2021, 60,430 people in the United States were evaluated to suffer from pancreatic cancer. The total number of cases is predicted to rise by 3.2 percent since the previous year. In addition, the strong presence of major market players is also expected to expand the region's market in the upcoming years. Moreover, rising occurrence of pancreatic adenocarcinoma and the growing establishment of critical care centers in the region will fuel the market expansion.
Europe Market Forecast
The European pancreatic adenocarcinoma treatment market is estimated to hold 26% share by the end of 2037, propelled by high consumption of alcohol and beverages across the region. Increasing research and development activities across the region for the invention in the discovery of new treatment procedures and drug therapies will hike the market revenue. The market growth is also attributed to the increasing number of people who smoke cigarettes across the region.
The growing number of people with obesity rates in the region will boost the market growth. The gastrointestinal problems and digestive issues in people owing to the high consumption of cheese and other sugary products will fuel the market size. The presence of many key players across the region who are investing in the research and development of diagnostic tests will have a positive impact on the market revenue. The presence of a very simple approval process for the new clinical trial drugs and treatment procedures in the region is also expected to drive the market growth.
APAC Market Statistics
The Asia Pacific market is predicted to register significant CAGR till 2037, due to well-established clinics in the region. The number of people suffering from pancreatic adenocarcinoma disease will propel the market revenue. The increasing number of diagnostic tests occurring in the region with a high prevalence rate is also driving the market growth.
The growing healthcare expenditure across the region to prevent the incidence of cancer will fuel the market growth. The rising pharmaceutical companies across the region with clinical trials to develop new drugs will hike the market revenue. The rising number of clinical care centers and hospitals with facilities for targeted therapy, chemotherapy, and radiotherapy is estimated to propel the market size. The increasing government initiatives to increase awareness among people regarding diagnostic awareness are driving the market growth across the region.
Companies Dominating the Pancreatic Adenocarcinoma Treatment Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffman-La Roche AG
- Novartis AG
- Pfizer Inc.
- Aduro Biotech Inc.
- Clovis Oncology Inc.
- Threshold Pharmaceuticals Inc.
- NewLink Genetics Corp
- Infinity Pharmaceuticals Inc.
- Celgene Corporation
In the News
-
Amgen Inc.’s new drug targeting KRAS mutations was approved by the U.S. Food and Drug Administration. This is the first-ever therapy developed to treat KRAS cancers, which are often altered in the colon, lung, and pancreatic areas.
-
Novartis AG declared that US Food and Drug Administration granted the NIS793 with Orphan Drug Designation (ODD) along with standard chemotherapy care for the treatment of pancreatic cancer.
Author Credits: Radhika Pawar
- Report ID: 3373
- Published Date: Apr 23, 2025
- Report Format: PDF, PPT
